Analysts See $-0.16 EPS for Aurinia Pharmaceuticals Inc. (AUPH)

July 21, 2018 - By Yee Bell

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Logo

Analysts expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to report $-0.16 EPS on August, 9.They anticipate $0.13 EPS change or 433.33 % from last quarter’s $-0.03 EPS. After having $-0.18 EPS previously, Aurinia Pharmaceuticals Inc.’s analysts see -11.11 % EPS growth. The stock increased 1.57% or $0.09 during the last trading session, reaching $5.81. About 275,791 shares traded. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has declined 11.38% since July 21, 2017 and is downtrending. It has underperformed by 23.95% the S&P500.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Coverage

Among 3 analysts covering Aurinia Pharmaceuticals (NASDAQ:AUPH), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals had 4 analyst reports since February 8, 2018 according to SRatingsIntel. Seaport Global maintained the shares of AUPH in report on Friday, March 16 with “Buy” rating. As per Thursday, March 15, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, May 10.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $499.70 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

More notable recent Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) news were published by: which released: “This Unloved Drug Stock Could Have Massive Upside” on July 18, 2018, also with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” published on July 12, 2018, published: “Aurinia Announces Results of Annual General Meeting” on June 22, 2018. More interesting news about Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were released by: and their article: “Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome” published on July 11, 2018 as well as‘s news article titled: “Aurinia Pharmaceuticals (AUPH) Commences Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for Treatment …” with publication date: July 11, 2018.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.